Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;52(8):e8443.
doi: 10.1590/1414-431X20198443. Epub 2019 Jul 29.

Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson's disease: a meta-analysis

Qian Wang  1 , Jianfang Liu  1 , Yikun Guo  1 , Guanzhong Dong  1 , Wenying Zou  1 , Zhuoyou Chen  1
Affiliations
Review

Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson's disease: a meta-analysis

Qian Wang et al. Braz J Med Biol Res. 2019.

Abstract

Brain-derived neurotrophic factor (BDNF) is widely expressed in the central nervous system and prolongs the survival of dopaminergic neurons in the substantia nigra. Several studies have recently investigated the association between BDNF G196A (Val66Met), a single nucleotide polymorphism influencing cognitive processes, and cognitive impairment in Parkinson's disease (PD), but with contradictory findings. Thus, this meta-analysis was performed to clarify the possible association. Relevant studies were identified by a systematic search of PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases. The strength of the association was evaluated using crude odds ratios and 95% confidence interval. Finally, six studies involving 532 cases and 802 controls were included. Our analyses suggested the G196A (Val66Met) polymorphism was significantly associated with cognitive impairment in PD, especially in Caucasian populations. In conclusion, BDNF G196A (Val66Met) is confirmed to be a risk factor for cognitive impairment in PD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Selection of publications included in this meta-analysis.
Figure 2.
Figure 2.. Forest plot showing odds ratio for the associations between rs6265 and cognitive impairment in PD (A: AA vs GA+GG; B: AA vs GA).
Figure 3.
Figure 3.. Stratification analyses of ethnicity between rs6265 and cognitive impairment in PD (A: AA vs GA+GG; B: AA vs GG; C: AA vs GA).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30:1591–1601. doi: 10.1002/mds.26424. - DOI - PubMed
    1. Winter Y, von Campenhausen S, Arend M, Longo K, Boetzel K, Eggert K, et al. Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. Parkinsonism Relat Disord. 2011;17:265–269. doi: 10.1016/j.parkreldis.2011.01.003. - DOI - PubMed
    1. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in parkinson's disease. Mov Disord. 2005;20:1255–1263. doi: 10.1002/mds.20527. - DOI - PubMed
    1. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology. 2001;56:730–736. doi: 10.1212/WNL.56.6.730. - DOI - PubMed
    1. O'Callaghan C, Lewis SJG. Cognition in Parkinson's disease. Int Rev Neurobiol. 2017;133:557–583. doi: 10.1016/bs.irn.2017.05.002. - DOI - PubMed

Substances